Hereditary Angioedema (HAE) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036

Hereditary Angioedema (HAE) Market Outlook

Thelansis’s “Hereditary Angioedema (HAE) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hereditary Angioedema (HAE) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Hereditary Angioedema (HAE) Overview

Hereditary angioedema (HAE) is a rare autosomal dominant disorder characterized by recurrent, self-limiting episodes of non-pruritic subcutaneous and submucosal edema affecting the skin, GI tract, and upper airway. Driven by SERPING1 mutations, Type I causes deficient C1-inhibitor (C1-INH) levels while Type II results in dysfunctional C1-INH protein, both leading to unregulated bradykinin production and vascular permeability. Attacks present as localized swelling or severe abdominal pain, with laryngeal edema posing a fatal asphyxiation risk. Diagnosis relies on low C4 levels and specific quantitative or functional C1-INH assays. While acute care historically required injectable C1-INH concentrates or the subcutaneous B2 receptor antagonist icatibant, the acute paradigm has been transformed by Ekterly (sebetralstat), the first oral plasma kallikrein inhibitor approved for on-demand use. Long-term prophylaxis has similarly advanced past traditional options like berotralstat or lanadelumab. Prophylactic protocols now feature Andembry (garadacimab), a monthly monoclonal antibody targeting Factor XIIa at the top of the cascade, alongside Dawnzera (donidalorsen), a first-in-class RNA-targeted antisense oligonucleotide that dampens prekallikrein production. Routine clinical tracking and prompt patient access to these targeted mechanisms are required to minimize attack frequency and guarantee safety.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2026–2036)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Hereditary Angioedema (HAE) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036